278 Oral Abstract Session, Thu, 1:30 PM-3:00 PM Results of The
ESOPHAGEAL AND GASTRIC CANCER 278 Oral Abstract Session, Thu, 1:30 PM-3:00 PM Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER22 advanced gastric or gastroesophageal junction cancer (GC/GEJC). Markus H. Moehler, Mikhail Dvorkin, Mustafa Ozguroglu, Min-hee Ryu, Alina Simona Muntean, Sara Lonardi, Marina Nechaeva, Arinilda Silva Campos Bragagnoli, Hasan Senol Coskun, Antonio Cubillo Graci´an, Toshimi Takano, Rachel Wong, Howard Safran, Gina M. Vaccaro, Narikazu Boku, Ilaria Conti, Janet Hong, Huiling Xiong, Julien Taieb, Yung-Jue Bang; Johannes Gutenberg-University Clinic, Mainz, Germany; Omsk Regional Clinical Centre of Oncology, Omsk, Russian Federation; Cerrahpas¸a School of Medicine, Istanbul University-Cerrahpas¸a, Istanbul, Turkey; Department of Oncology, Asan Medical Center, Seoul, South Korea; "Prof. Dr. Ion Chiricut¸a"˘ Institute of Oncology, Cluj-Napoca, Romania; Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy; Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Barretos Cancer Hospital, Barretos, Brazil; Akdeniz University, Antalya, Turkey; HM Universitario Sanchinarro, Madrid, Spain; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan; Eastern Health, Monash University, Melbourne, Australia; Brown University Oncology Research Group, Providence, RI; Oregon Health & Science University, Portland, OR; National Cancer Center Hospital, Tokyo, Japan; EMD Serono, Billerica, MA; Merck Serono, Beijing, China; Hopitalˆ Europ´een Georges-Pompidou, Sorbonne Paris Cite/Paris Descartes University, Paris, France; Seoul National University Hospital, Seoul, South Korea Background: We report the primary analysis of JAVELIN Gastric 100, which compared avelumab (anti–PD-L1) maintenance after 1L CTx vs continued CTx in patients (pts) with GC/GEJC.
[Show full text]